AR111494A1 - Compuestos de anilinoquinazolina c₅ y su uso en el tratamiento del cáncer - Google Patents

Compuestos de anilinoquinazolina c₅ y su uso en el tratamiento del cáncer

Info

Publication number
AR111494A1
AR111494A1 ARP180101102A ARP180101102A AR111494A1 AR 111494 A1 AR111494 A1 AR 111494A1 AR P180101102 A ARP180101102 A AR P180101102A AR P180101102 A ARP180101102 A AR P180101102A AR 111494 A1 AR111494 A1 AR 111494A1
Authority
AR
Argentina
Prior art keywords
hydrogen
anilinoquinazoline
compounds
cancer treatment
alkoxy
Prior art date
Application number
ARP180101102A
Other languages
English (en)
Inventor
Tudor Grecu
James Michael Smith
Stuart Eric Pearson
Martin John Packer
Jason Grant Kettle
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR111494A1 publication Critical patent/AR111494A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Abstract

El proceso para su preparación; las composiciones farmacéuticas que los contienen y su uso en el tratamiento de las enfermedades mediadas por KIT. Reivindicación 1: Un compuesto de la fórmula (1), o una sal del mismo aceptable desde el punto de vista farmacéutico, caracterizado porque: R¹ se selecciona de hidrógeno y flúor; R² se selecciona de flúor y alcoxi C₁₋₂; R³ se selecciona de hidrógeno y metoxi; y R⁴ es un alquilo C₁₋₃, opcionalmente sustituido con un grupo seleccionado de alcoxi C₁₋₃ y NR⁵R⁶, en donde R⁵ y R⁶ son cada uno independientemente hidrógeno o metilo; o un anillo de heterociclilo de 4 a 6 elementos que contiene un átomo de oxígeno.
ARP180101102A 2017-04-27 2018-04-27 Compuestos de anilinoquinazolina c₅ y su uso en el tratamiento del cáncer AR111494A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762490859P 2017-04-27 2017-04-27

Publications (1)

Publication Number Publication Date
AR111494A1 true AR111494A1 (es) 2019-07-17

Family

ID=62091877

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP180101102A AR111494A1 (es) 2017-04-27 2018-04-27 Compuestos de anilinoquinazolina c₅ y su uso en el tratamiento del cáncer

Country Status (14)

Country Link
US (2) US10273227B2 (es)
EP (1) EP3615522B1 (es)
JP (1) JP7128204B2 (es)
KR (1) KR102603153B1 (es)
CN (1) CN110573505B (es)
AR (1) AR111494A1 (es)
AU (1) AU2018259078B2 (es)
BR (1) BR112019022229A2 (es)
CA (1) CA3059283A1 (es)
ES (1) ES2888298T3 (es)
MX (1) MX2019012847A (es)
RU (1) RU2769694C2 (es)
TW (1) TWI774758B (es)
WO (1) WO2018197642A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018197642A1 (en) * 2017-04-27 2018-11-01 Astrazeneca Ab C5-anilinoquinazoline compounds and their use in treating cancer
KR20230066583A (ko) 2020-09-10 2023-05-16 젠맵 에이/에스 미만성 대 b-세포 림프종을 치료하기 위한 조합 요법에서의 cd3 및 cd20에 대한 이중특이적 항체
MX2023002540A (es) 2020-09-10 2023-03-14 Genmab As Anticuerpo biespecifico contra el cumulo de diferenciacion 3 (cd3) y el cumulo de diferenciacion 20 (cd20) en terapia combinada para el tratamiento del linfoma folicular.
US20230357440A1 (en) 2020-09-10 2023-11-09 Genmab A/S Bispecific antibody against cd3 and cd20 in combination therapy for treating follicular lymphoma
AU2021342342A1 (en) 2020-09-10 2023-04-13 Genmab A/S Bispecific antibodies against CD3 and CD20 for treating chronic lymphocytic leukemia
JP2023542291A (ja) 2020-09-10 2023-10-06 ジェンマブ エー／エス びまん性大細胞型ｂ細胞リンパ腫を治療するための併用療法におけるｃｄ３及びｃｄ２０に対する二重特異性抗体
US20240116877A1 (en) * 2021-12-09 2024-04-11 Deciphera Pharmaceuticals, Llc Kit kinase inhibitors and methods of use thereof

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9510757D0 (en) 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
GB9514265D0 (en) 1995-07-13 1995-09-13 Wellcome Found Hetrocyclic compounds
DE60043349D1 (de) 1999-09-21 2009-12-31 Astrazeneca Ab Chinazolin-derivate und ihre verwendung als arzneimittel
NZ529046A (en) 2001-04-27 2005-10-28 Kirin Brewery Quinoline derivative having azolyl group and quinazoline derivative
TW200505452A (en) * 2003-06-17 2005-02-16 Astrazeneca Ab Chemical compounds
EP1684762A4 (en) * 2003-11-13 2009-06-17 Ambit Biosciences Corp UREA DERIVATIVES AS MODULATORS OF KINASE
NZ554017A (en) 2004-10-12 2010-06-25 Astrazeneca Ab [(Quinazolin-4-yloxy)phenyl]acetamide derivatives
JO2787B1 (en) 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
US20070106549A1 (en) 2005-11-04 2007-05-10 Stocking Christine A Turnkey aviation budget management
UY30183A1 (es) 2006-03-02 2007-10-31 Astrazeneca Ab Derivados de quinolina
WO2008089307A2 (en) 2007-01-18 2008-07-24 Lexicon Pharmaceuticals, Inc. Delta 5 desaturase inhibitors for the treatment of pain, inflammation and cancer
US20080200458A1 (en) 2007-01-18 2008-08-21 Joseph Barbosa Methods and compositions for the treatment of body composition disorders
TWI377944B (en) * 2007-06-05 2012-12-01 Hanmi Holdings Co Ltd Novel amide derivative for inhibiting the growth of cancer cells
EP2288383A1 (en) 2008-05-14 2011-03-02 Amgen, Inc Combinations vegf(r) inhibitors and hepatocyte growth factor (c-met) inhibitors for the treatment of cancer
WO2011153553A2 (en) 2010-06-04 2011-12-08 The Regents Of The University Of California Methods and compositions for kinase inhibition
CN102532042A (zh) * 2010-12-30 2012-07-04 上海医药工业研究院 一种芳基脲类化合物、其中间体及其应用
WO2012155339A1 (zh) * 2011-05-17 2012-11-22 江苏康缘药业股份有限公司 4-苯胺-6-丁烯酰胺-7-烷醚喹唑啉衍生物及其制备方法和用途
CN103254142B (zh) 2013-04-26 2015-10-28 浙江工业大学 4-[4-(2-取代氨基乙酰氨基)苯胺基]喹唑啉类衍生物及制备和应用
WO2014181287A1 (en) 2013-05-09 2014-11-13 Piramal Enterprises Limited Heterocyclyl compounds and uses thereof
CN104130200B (zh) 2014-07-01 2016-04-20 中山大学 一种2-取代苯基-4-芳胺基喹唑啉衍生物及其制备方法和应用
CA3059660A1 (en) 2017-04-27 2018-11-01 Astrazeneca Ab Phenoxyquinazoline compounds and their use in treating cancer
WO2018197642A1 (en) * 2017-04-27 2018-11-01 Astrazeneca Ab C5-anilinoquinazoline compounds and their use in treating cancer

Also Published As

Publication number Publication date
RU2019136279A3 (es) 2021-05-31
KR20190141203A (ko) 2019-12-23
TWI774758B (zh) 2022-08-21
TW201904960A (zh) 2019-02-01
BR112019022229A2 (pt) 2020-05-12
RU2019136279A (ru) 2021-05-27
US20190263787A1 (en) 2019-08-29
WO2018197642A1 (en) 2018-11-01
CA3059283A1 (en) 2018-11-01
KR102603153B1 (ko) 2023-11-15
US10273227B2 (en) 2019-04-30
CN110573505A (zh) 2019-12-13
US20180312490A1 (en) 2018-11-01
RU2769694C2 (ru) 2022-04-05
ES2888298T3 (es) 2022-01-03
US10829479B2 (en) 2020-11-10
JP2020517677A (ja) 2020-06-18
AU2018259078B2 (en) 2021-10-07
EP3615522A1 (en) 2020-03-04
MX2019012847A (es) 2022-01-07
AU2018259078A1 (en) 2019-10-17
CN110573505B (zh) 2023-04-11
JP7128204B2 (ja) 2022-08-30
EP3615522B1 (en) 2021-08-04

Similar Documents

Publication Publication Date Title
AR111494A1 (es) Compuestos de anilinoquinazolina c₅ y su uso en el tratamiento del cáncer
AR110400A1 (es) Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer
PE20190326A1 (es) Isoquinolin-3-il-carboxamidas y preparacion y uso de las mismas
NI201700020A (es) Compuestos de aminopirimidinilo como inhibidores de jak
AR106053A1 (es) Compuestos imidazo[4,5-c]quinolin-2-ona y su uso para el tratamiento del cáncer
AR107032A1 (es) Inhibidores bicíclicos de pad4
AR104176A1 (es) Inhibidores de ido (indolamina-2,3-dioxigenasa)
AR089671A1 (es) 1,4-dihidropirimidinas 4,4-disustituidas y su uso como medicamentos para el tratamiento de la hepatitis b
AR103251A1 (es) Compuestos policíclicos de carbamoilpiridona y su uso farmacéutico
AR114971A1 (es) Compuestos de purinona y su uso en el tratamiento del cáncer
AR100340A1 (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer
AR093818A1 (es) Compuesto de 1-(bencil sustituido)piperazina sustituida
AR094784A1 (es) Compuestos de tubulisina, métodos para obtenerlos y uso
AR099228A1 (es) Inhibidores macrocíclicos de fxia que tienen grupos heterocíclicos
AR095885A1 (es) Compuestos derivados de arilpirrolopiridina como inhibidores de lrrk2
AR106865A1 (es) Piridinas sustituidas y métodos de uso
AR097325A1 (es) Pirroles anillados
AR103232A1 (es) ANTAGONISTAS DE TGFbR
AR107054A1 (es) DERIVADOS DE ISOINDOL Y COMPOSICIONES FARMACÉUTICAS QUE LOS COMPRENDEN PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR RORg Y RORgt
AR094553A1 (es) Formas de oxadiazolpirazina
AR093937A1 (es) Compuestos quimicos
AR112086A1 (es) Compuestos heteroaromáticos como inhibidores de vanina
AR101479A1 (es) Derivados de 6-alquinil-piridina
AR109706A1 (es) INHIBIDORES DUALES DE FOSFATIDILINOSITOL 3 QUINASA d / g
AR098723A1 (es) Derivados de pirazolopirimidin-2-ilo como inhibidores de jak